Journal of the Chemical Society. Perkin transactions I p. 2573 - 2576 (1985)
Update date:2022-08-04
Topics:
Seela, Frank
Steker, Herbert
Phase-transfer glycosylation of 4-chloro-1H-pyrazolo<3,4-d>pyrimidine (1) with 2-deoxy-3,5-di-O-(p-toluoyl)-α-D-erythro-pentofuranosyl chloride (2) yielded the N-1 glycosylation product (3) in 42 percent.The protected intermediate (3) was converted into pyrazolo<3,4-d>pyrimidine 2'-deoxyribofuranosides with amino, oxo, and thioxo substituents at C-4.Kinetic data of proton-catalysed hydrolysis showed that pyrazolo<3,4-d>pyrimidine 2'-deoxyribofuranosides are more stable at the N-glycosylic bond than are the parent purine nucleosides.
View MoreTaimai Sanluck Pharmaceutical Co.,Ltd
Contact:86-592-7662921
Address:8D,No.186,Huarong Road,Huli,Xiamen,China
Wuhan Sunrise Pharmaceutical Technology Co., Ltd
Contact:+86-27-83314682
Address:Room 340, New material Industrial base No.17, Gu Tian Five Lu , Qiaokou District, Wuhan , China
Contact:+86-13666670345
Address:Agricultural Development Zone, Haining, Jiaxing, Zhejiang
Xi'an Unique Electronic and Chemical Co., Ltd.
Contact:+86-029-88238008
Address:1703# B BUILDING WEST ELECTRONIC ZONE, XI'AN, CHINA
Guangzhou PI & PI Biotech Inc. Ltd.
Contact:+86-20-81716320
Address:13th Floor, Xinbao Technology Industrial Park, No. 2 Ruixiang Road, Huangpu District, Guangzhou,Guangdong,China
Doi:10.1021/jo01369a017
(1954)Doi:10.1016/j.ica.2019.02.007
(2019)Doi:10.1055/s-0037-1612423
(2019)Doi:10.1016/j.bmc.2007.12.021
(2008)Doi:10.1016/S0009-3084(01)00152-9
(2001)Doi:10.1016/j.bmc.2007.12.001
(2008)
